Author(s): Dmling A, Holak TA
Abstract Share this page
Abstract No other cancer therapy target class caused more excitement than the programmed death-1 (PD-1) pathway related. Antibodies against PD-1 and PD-1 ligands represent a therapeutic breakthrough and are the first examples of broadly efficacious and durable cancer immunotherapies. Cancer for the first time seems to have transformed from an often incurable to a "clinically manageable" disease. Copyright © 2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
This article was published in Angew Chem Int Ed Engl
and referenced in Journal of Pharmaceutical Care & Health Systems